Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?
about
Monitoring of pathogen-specific T-cell immune reconstitution after allogeneic hematopoietic stem cell transplantationHow I treat pediatric acute myeloid leukemiaChildhood acute myeloid leukaemiaOutcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant.Current Management of Childhood Acute Myeloid Leukemia.Costs of second allogeneic hematopoietic cell transplantation.Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis.The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromesSurvival Impact of Early Post-Transplant Toxicities in Pediatric and Adolescent Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Malignant and Nonmalignant Diseases: Recognizing Risks and Optimizing OutcomesSignificant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent eraFate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia.The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.Functional status and health-related quality of life among allogeneic transplant patients at hospital discharge: a comparison of sociodemographic, disease, and treatment characteristics.Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients.Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease.Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease.Prevalence of hematopoietic cell transplant survivors in the United States.Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.Total Body Irradiation without Chemotherapy as Conditioning for an Allogeneic Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia.Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation.Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis.Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions.Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma.Caregiver Sleep and Patient Neutrophil Engraftment in Allogeneic Hematopoietic Stem Cell Transplant: A Secondary Analysis.Aging: Treating the Older Patient.Pre-transplant diabetes mellitus is a risk factor for non-relapse mortality, especially infection-related mortality, after allogeneic hematopoietic SCT.Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation.Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation.PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes.Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012.Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation.Causes of mortality after haploidentical hematopoietic stem cell transplantation and the comparison with HLA-identical sibling hematopoietic stem cell transplantation.Acute GVHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine/melphalan conditioning.Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time.To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decisionCentral nervous system complications after allogeneic hematopoietic stem cell transplantation.Similar survival, but better quality of life after myeloablative transplantation using unrelated cord blood vs matched sibling donors in adults with hematologic malignancies.
P2860
Q26861648-20DA4A80-486B-4430-A836-E86428BEEA20Q26992280-A0623BFA-EE4B-43C7-9BA6-AB477429CCF3Q27005960-A7608BB4-9F59-4120-95C4-6279C6D27174Q30240140-E80C4591-2495-495E-835D-305A0DDF7D94Q30244036-2BABC7AD-5BA2-4231-9404-68A674634297Q30540989-00867F04-37D9-41D3-8582-1CC62158611DQ30577948-4436E340-E46F-49FA-A01A-A91BC47C5762Q33573495-81624432-4CA9-48ED-ABC9-EECA8F9DEC02Q33870341-FE77EDC5-9817-4574-9120-96D80531CDCDQ34749365-412197A0-2337-4D3B-963C-FF40076E01AFQ35285004-B1006355-EE6C-4000-A6FC-F7DFF9724893Q35782852-0A255B74-1274-4132-9E71-8BEE65046AF6Q35849342-95AABA46-2345-4145-AEA7-0AD30EA6E1FEQ36087195-DDC627BA-0A2B-469C-AD86-61933B236391Q36264692-471CB604-9004-4E26-876A-1AFC255B2437Q36543686-4630A65C-CC6D-432D-BDEE-0B0C913FA490Q36715943-4463AD5B-F5AD-46BC-ACAA-4FAD7CAF5A8BQ37188807-DF650C07-9DA0-4FA3-ACC3-387A19C4D097Q37370651-047696AC-07EE-4931-871F-F6DB6607D90AQ37443163-EAB06637-6459-46C6-AA9B-6E209C86BFACQ37575215-E707773E-EFB0-4104-9949-6B274A519CA8Q38018908-ED57292E-5EAD-4C76-84DD-B44E779A4466Q38143516-0B23B9BA-40F4-443B-9D6A-065BD7389237Q38207595-3206BEDF-9554-413D-8418-8EE23CBA0367Q38777460-3C6E28A5-C166-4716-B2B9-B9FED4EEBDC9Q38786591-23CE2E57-D566-430F-96D1-74F8E676E6FAQ39013605-0B415319-7676-44B2-98F4-741A6EE67B9CQ39049349-4489D0CA-41AB-4593-8A15-B40080811486Q39716725-994F7B72-05E7-44EF-A732-E250D84D8325Q40122841-FAE45C61-A2C2-4EAF-AA99-63F8E38DB65EQ40216708-3E6D8BF1-4903-46A2-8BE8-E277C18E0E3CQ40288619-FF2CCC5C-710E-4834-B0E1-0B30D1AB1E4EQ40727176-6EC9CB86-C198-4A4C-B232-9DABC96400C2Q40799791-62AAAD92-071B-4884-B49C-5558A2FBDBB7Q41031192-91836CC5-4BF3-4D25-A0D0-A3DD48CE4BB3Q41663868-FF925356-15B1-4975-BFAD-8B2E3467336CQ41688144-7186A33C-A082-4385-A2D8-3949E3A48D34Q41879404-F51911F0-DDC0-4768-8D1E-7D899F796DE6Q41923053-C345CD4D-4298-4D0B-9643-879BD35D5E94Q44059940-AACEA850-6898-4190-897B-1274151ED75F
P2860
Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Reducing the risk for transpla ...... w much progress has been made?
@ast
Reducing the risk for transpla ...... w much progress has been made?
@en
Reducing the risk for transpla ...... w much progress has been made?
@nl
type
label
Reducing the risk for transpla ...... w much progress has been made?
@ast
Reducing the risk for transpla ...... w much progress has been made?
@en
Reducing the risk for transpla ...... w much progress has been made?
@nl
prefLabel
Reducing the risk for transpla ...... w much progress has been made?
@ast
Reducing the risk for transpla ...... w much progress has been made?
@en
Reducing the risk for transpla ...... w much progress has been made?
@nl
P2093
P2860
P356
P1476
Reducing the risk for transpla ...... w much progress has been made?
@en
P2093
Andrea A Bacigalupo
Brent R Logan
Christopher N Bredeson
Franklin O Smith
Gregory A Hale
Hanna Jean Khoury
J Douglas Rizzo
John T Horan
Karen K Ballen
Manza-A Agovi-Johnson
P2860
P304
P356
10.1200/JCO.2010.32.5001
P407
P577
2011-01-10T00:00:00Z